Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Non-Current Assets (2022 - 2025)

Historic Non-Current Assets for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to $107.0 million.

  • Century Therapeutics' Non-Current Assets fell 4140.02% to $107.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $536.7 million, marking a year-over-year decrease of 2627.77%. This contributed to the annual value of $159.2 million for FY2024, which is 1335.46% down from last year.
  • Per Century Therapeutics' latest filing, its Non-Current Assets stood at $107.0 million for Q3 2025, which was down 4140.02% from $124.5 million recorded in Q2 2025.
  • In the past 5 years, Century Therapeutics' Non-Current Assets registered a high of $255.9 million during Q2 2023, and its lowest value of $107.0 million during Q3 2025.
  • Its 4-year average for Non-Current Assets is $173.0 million, with a median of $166.8 million in 2022.
  • As far as peak fluctuations go, Century Therapeutics' Non-Current Assets skyrocketed by 7197.21% in 2023, and later plummeted by 4152.97% in 2025.
  • Century Therapeutics' Non-Current Assets (Quarter) stood at $166.8 million in 2022, then grew by 10.11% to $183.7 million in 2023, then fell by 13.35% to $159.2 million in 2024, then plummeted by 32.77% to $107.0 million in 2025.
  • Its Non-Current Assets stands at $107.0 million for Q3 2025, versus $124.5 million for Q2 2025 and $146.0 million for Q1 2025.